吉法匹生片的用药指南

Gefapixant is the world's first P2X3 receptor antagonist, providing an innovative treatment option for patients with refractory chronic cough. This drug, jointly developed by Merck and Japan's Kyorin Pharmaceuticals, uses a unique mechanism to act on the airway vagus nerve. This article will elaborate on the medication specifications, drug interaction characteristics and medication regimens for special populations of Gemfapixin Tablets, and provide comprehensive guidance for rational clinical use of medications.

Medication Guidelines for Gemfapixin Tablets

Standard use requires strict compliance with the dosage regimen and administration requirements, and medication needs to be administered under the guidance of a doctor.

Standard dosage regimen

The usual adult dose is 45 mg twice daily, taken orally about 12 hours apart. It is recommended to take the medicine at a fixed time, and it can be taken with food or alone. Eating will not affect the absorption of the medicine.

Principles of dose adjustment

Patients with severe renal insufficiency (eGFR <30mL/min) should adjust to 45 mg once daily. When moderate to severe adverse reactions occur, temporary discontinuation or dose reduction may be considered, and treatment may be restarted at a lower dose after symptoms are relieved.

Dosing Precautions

The tablet must be swallowed whole and must not be broken, crushed or chewed. PTP packaging must be opened correctly to avoid esophageal damage caused by accidentally swallowing aluminum foil. If you miss a dose, you do not need to make up the dose. Take the next dose as originally planned.

Following these medication guidelines can reduce the risk of adverse reactions.

Drug interactions of Gemfapisen tablets

Understanding the drug interaction characteristics of Gemfapisene tablets is of great significance for formulating a reasonable combination medication regimen.

Transporter interaction

As a substrate of MATE1/2-K and P-gp, combination with potent transporter inhibitors may increase plasma concentrations. Clinical data indicate that these interactions are not clinically significant at conventional doses.

Metabolic enzyme effects

It is not metabolized by CYP enzymes, and no dose adjustment is required when combined with CYP inhibitors or inducers. It has a slight inhibitory effect on OATP1B1/1B3, but no significant effect was seen in combination with substrates such as pitavastatin.

Renally excreted drugs

Mainly excreted by the kidneys. When combined with drugs that are also excreted by the kidneys, attention should be paid to changes in renal function, especially in elderly patients and those with renal insufficiency.

Understanding these interaction characteristics can help avoid unnecessary medication risks.

Medication of Gemfapisene Tablets for Special Populations

Different groups of people have different reactions to Gyfapisene Tablets, and individualized medication strategies need to be developed.

Patients with renal insufficiency

For severe renal impairment, the dose should be reduced to once a day. Data are limited in patients with end-stage renal disease and should be used with caution. Patients with mild to moderate renal insufficiency do not need to adjust the dosage, but increased monitoring is required.

Patients with abnormal liver function

No dose adjustment is required for mild to moderate liver impairment. Contraindicated in severe hepatic impairment (Child-Pugh class C) due to lack of safety data.

People with special physiological conditions

Contraindicated for pregnant women; lactating women should suspend breastfeeding; safety for children under 18 years old has not been established; the elderly need to adjust the monitoring frequency according to renal function.

Adjusting medication regimens based on the characteristics of different groups of people can maximize the balance between efficacy and safety and achieve individualized treatment.